1. Homepage
  2. Equities
  3. Bangladesh
  4. Dhaka Stock Exchange
  5. Beximco Pharmaceuticals Limited
  6. News
  7. Summary
    BXPHARMA   BD0453BXPH04

BEXIMCO PHARMACEUTICALS LIMITED

(BXPHARMA)
  Report
End-of-day quote Dhaka Stock Exchange  -  05-18
150.20 BDT   -0.53%
04/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
CI
04/01Beximco Pharmaceuticals Renames Sanofi Bangladesh Subsidiary To Synovia Pharma
MT
03/17Beximco Lands Sub-License From United Nations-Backed Program For COVID-19 Treatment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Beximco Jumps 6% on License to Produce Merck & Co.'s COVID-19 Drug in Bangladesh

01/20/2022 | 04:52am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BEXIMCO PHARMACEUTICALS LIMITED -0.53% 150.2 End-of-day quote.-22.06%
MERCK & CO., INC. -0.01% 92.09 Delayed Quote.20.16%
ON SEMICONDUCTOR CORPORATION 0.43% 56.07 Delayed Quote.-17.45%
All news about BEXIMCO PHARMACEUTICALS LIMITED
04/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine..
CI
04/01Beximco Pharmaceuticals Renames Sanofi Bangladesh Subsidiary To Synovia Pharma
MT
03/17Beximco Lands Sub-License From United Nations-Backed Program For COVID-19 Treatment
MT
03/17United Nations-Backed Medicines Patent Pool Grants Beximco Pharmaceuticals Limited's Su..
CI
01/28Earnings Flash (BXP.L) BEXIMCO PHARMACEUTICALS Posts Fiscal H1 Revenue $17M
MT
01/28Earnings Flash (BXP.L) BEXIMCO PHARMACEUTICALS Posts Fiscal H1 EPS $7.12
MT
01/28Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six..
CI
01/20Beximco Jumps 6% on License to Produce Merck & Co.'s COVID-19 Drug in Bangladesh
MT
01/20Dozens of firms to make cheap version of Merck COVID pill for poorer nations
RE
01/20Beximco Pharmaceuticals Limited Granted License to Produce Molnupiravir for Covid-19
CI
More news
Financials
Sales 2022 34 856 M 405 M 405 M
Net income 2022 6 242 M 72,5 M 72,5 M
Net Debt 2022 9 750 M 113 M 113 M
P/E ratio 2022 9,95x
Yield 2022 2,93%
Capitalization 67 006 M 778 M 778 M
EV / Sales 2022 2,20x
EV / Sales 2023 1,87x
Nbr of Employees 5 500
Free-Float 94,3%
Chart BEXIMCO PHARMACEUTICALS LIMITED
Duration : Period :
Beximco Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 150,20 BDT
Average target price 182,00 BDT
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Nazmul Hassan Chief Executive Officer, Director & MD
Mohammad Ali Nawaz Chief Financial Officer
Ahmed Sohail Fasihur Rahman Chairman
Selina Akter Executive Director-Medical Affairs Department
Rabbur Reza Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BEXIMCO PHARMACEUTICALS LIMITED-22.06%778
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689